Todd Wood joins Obalon Therapeutics, Inc. as Vice President Global Sales

SAN DIEGO, May 07, 2018 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Todd Wood has joined as Vice President Global Sales. Mr. Wood will be responsible for leading field sales, product specialists, sales operations and inside sales support.

“Mr. Wood brings deep expertise in high-touch physician relationships and practice engagement to create sustainable revenue in developing markets. He was instrumental in building the Botox Cosmetic field force at Allergan, along with a unique selling model concentrated on business and practice development services, which makes him uniquely qualified to help lead Obalon’s next phase of growth,” stated Kelly Huang, Ph.D., Chief Operating Officer.

“Mr. Wood has a strong record of creating and developing high performance sales teams through his 24 years at Allergan. He has held sales leadership positions in both medical device and cash-pay aesthetics industries, which provides a strong fit for Obalon’s current and future needs as we continue to develop the market for the Obalon Balloon,” commented Andy Rasdal, Chief Executive Officer of Obalon.

Mr. Wood was most recently Vice President Sales, U.S. Dermatology for Allergan where he created and implemented an expansion plan for product launch. Prior to that, he was Vice President Sales, U.S. Eye Care for Allergan where he developed the strategic sales infrastructure for the entire U.S. Eye Care sales organization. 

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of Obalon’s product. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Obalon believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements. Forward-looking statements are subject to risks and uncertainties that may cause Obalon’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the anticipated adoption of the Obalon balloon system by members of the Sono Bello practice group and its patients; the company’s ability to achieve or sustain profitability; the company’s ability to predict its future prospects and forecast its financial performance and growth; the rate at which physicians and patients adopt and use the company’s balloon system; the effect of adverse events or other negative developments involving other companies’ intragastric balloons or other obesity treatments; the company’s ability to educate physicians on safe and proper use of the Obalon balloon system; the rate at which patients may experience serious adverse device events as the result of the misuse or malfunction of, or design flaws in, the company’s products; the company’s ability to obtain FDA approval or other regulatory approvals for its future products and product improvements; the company’s ability to adequately protect its proprietary technology and maintain its issued patents and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
[email protected]

Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 1565
[email protected]